MannKind grants United Therapeutics rights to treprostinil for PAH
MannKind Corp. licensed United Therapeutics Corp. exclusive worldwide rights to develop and commercialize a dry powder formulation of treprostinil, which is currently in Phase I for pulmonary arterial hypertension.
- Medical Devices
- Drug Delivery
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.